Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
2011 · Nature Medicine · 514 citations
https://doi.org/10.1038/nm.2309
P
Ping Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
150
Papers
5.1K
Citations
29
h-index
51
i10-index
Ping Li is an academic researcher from Tongji University. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Immunodeficiency and Autoimmune Disorders & Chronic Myeloid Leukemia Treatments. The author has an h-index of 29, co-authored 128 publications.
ORCID: 0000-0002-0195-0871Papers by this author
worksEvaluation of human and non‐human primate antibody binding to pig cells lacking <scp>GGTA</scp>1/<scp>CMAH</scp>/β4Gal<scp>NT</scp>2 genes
2015 · Xenotransplantation · 385 citations
https://doi.org/10.1111/xen.12161
Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance
2009 · Clinical Cancer Research · 79 citations
https://doi.org/10.1158/1078-0432.ccr-08-0954
GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
2022 · Cell Death and Disease · 20 citations
https://doi.org/10.1038/s41419-022-04932-4
Immunochemotherapeutic nanoparticles inhibit cancer-promoting fibroblasts subtypes for pancreatic ductal adenocarcinoma
2025 · Nano Today · 5 citations
https://doi.org/10.1016/j.nantod.2025.102709
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat